Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Theriva Biologics is a clinical-stage biotech developing cancer therapeutics, notably oncolytic viruses like VCN-01 for solid tumors and pancreatic cancer. Its platform leverages virus-induced tumor cell destruction and immune activation, with potential for intravenous delivery. The company also explores microbiome-focused therapies for infections like C. difficile and VRE, aiming to address high unmet medical needs in oncology and infectious diseases.
This description was generated via AI from an annual report. Updated about 1 year ago.